

VACUNA CONTRA EL VPH

Hoy día se trabaja en el desarrollo de VACUNAS POLIVALENTES

La primera vacuna aprobada en EEUU, Gardasil, está diseñada para prevenir la infección por 4 de las cepas del virus específicas

La 16-18, responsables del 70% de los tumores del cuello del útero

Los subtipos 6 y 11 que se asocian con el 90% de las verrugas genitales



VACUNA TETRAVALENTE “GARDASIL”

Aprobada el 6 de agosto del 2006 por la FDA (FOOD and DRUGS ADMINISTRATION)

Para prevenir el cáncer cervicouterino y las verrugas virales (condilomas).

También para evitar lesiones cervicales, vaginales, anales y penianas .



U.S. Food and Drug Administration

CENTER FOR BIOLOGICS EVALUATION AND RESEARCH

[FDA Home Page](#) | [CBER Home Page](#) | [CBER A-Z Index](#) | [CBER Site Map](#) | [Contact CBER](#)

Department of Health and Human Services

Search

GO

powered by Google

CBER Information

- About CBER
- CBER's Email Lists
- Contact CBER
- Frequently Asked Questions
- Jobs at CBER
- Organization Charts

Useful Government Sites

- VAERS
- FIRSTGOV

Product Approval Information - Licensing Action


Proper name: **Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine**
Tradename: **GARDASIL**
Manufacturer: **Merck & Co., Inc., West Point, PA, License #0002**
Indication for Use: **Vaccination in females 9 to 26 years of age for prevention of the following diseases caused by Human Papillomavirus (HPV) Types 6, 11, 16, and 18:**

- Cervical cancer
- Genital warts (condyloma acuminata) and the following precancerous or dysplastic lesions:
- Cervical adenocarcinoma in situ (AIS)
- Cervical intraepithelial neoplasia (CIN) grade 2 and grade 3
- Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3
- Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3
- Cervical intraepithelial neoplasia (CIN) grade 1

Approval Date: 6/8/2006
Type of submission: **Biologics license application**
STN: 125126.0

[Letter](#)
[Label \(PDF\)](#)
[Label \(Text\)](#)

ESQUEMA DE VACUNACION



Referencias:

- 1.- Gardasil vacuna, monografía, www.msd.com.mx
- 2.- World Health Organization. The current status of development of prophylactic vaccines against human papillomavirus infection. Report of a technical meeting,

16–18 February 1999. Geneva, Switzerland: World Health Organization; 1999:1–22.

- 3.- Bosch FX aA, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. *J Clin Pathol*. 2002;55(4):244-65
- 5.- Bleeker MC, Hogewoning CJ, Voorhorst FJ, van Den Brule AJ, y cols Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplastic. *Int J Cancer*. 2003; 107(5):804-10
- 6.- Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P y cols. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. *Lancet*. 2001;357 (9271):1831-6.
- 7. -Howley PM, Lowy DR. En: Knipe DM, Howley PM, eds. Philadelphia, Pa: Lippincott-Raven; 2001:2197–2229.
- Schiffman M, Castle PE. *Arch Pathol Lab Med*. 2003;127:930–934.
- 8.-Wiley DJ, Douglas J, Beutner K, y cols. *Clin Infect Dis*. 2002;35(suppl 2):S210–S224.
- Muñoz N, Bosch FX, Castellsagué X, y cols. *Int J Cancer*. 2004;111:278–285.

